Daily Cardiology Research Analysis
Three high-impact cardiology studies stood out: AI-derived left ventricular mass from routine non-contrast CT independently predicted long-term MACE beyond coronary calcium; genetic predisposition to higher LDL-C was inversely associated with incident type 2 diabetes risk, clarifying lipid–diabetes trade-offs; and a comprehensive meta-analysis showed that antiparasitic therapy in chronic Chagas disease reduces ECG progression, disease progression, cardiovascular death, and all-cause mortality.
Summary
Three high-impact cardiology studies stood out: AI-derived left ventricular mass from routine non-contrast CT independently predicted long-term MACE beyond coronary calcium; genetic predisposition to higher LDL-C was inversely associated with incident type 2 diabetes risk, clarifying lipid–diabetes trade-offs; and a comprehensive meta-analysis showed that antiparasitic therapy in chronic Chagas disease reduces ECG progression, disease progression, cardiovascular death, and all-cause mortality.
Research Themes
- AI-enabled cardiac imaging risk stratification
- Genetic architecture of lipid–diabetes interactions
- Global cardiomyopathy therapy effectiveness (Chagas disease)
Selected Articles
1. AI-derived automated quantification of cardiac chambers and myocardium from non-contrast CT: Prediction of major adverse cardiovascular events in asymptomatic subjects.
In a 2,022-participant cohort with 13.9 years follow-up, AI-quantified left ventricular mass from routine non-contrast CT independently predicted MACE beyond coronary calcium score and improved discrimination and reclassification. LV mass, but not CAC, predicted cardiovascular death.
Impact: This study repurposes widely available calcium-scoring CT with AI to extract prognostically powerful cardiac phenotypes, enabling low-cost, population-scale risk stratification.
Clinical Implications: Incorporating AI-derived LV mass into reporting for non-contrast CAC scans can refine long-term risk assessment and potentially guide preventive therapy intensity beyond CAC alone.
Key Findings
- AI-quantified LV mass from non-contrast CT independently predicted long-term MACE (HR 2.76, p<0.001) after multivariable adjustment.
- Adding LV mass to CAC improved AUC (0.753→0.767; p=0.031) and achieved a continuous NRI of 18% (p=0.011).
- LV mass predicted cardiovascular death (HR 3.89, p<0.001), whereas CAC did not.
Methodological Strengths
- Long-term follow-up (mean 13.9 years) in a well-characterized cohort (EISNER).
- Deep-learning segmentation enabling standardized, automated quantification from routine non-contrast CT.
Limitations
- Single-trial cohort; external validation in diverse populations and scanners was not reported.
- Observational design limits causal inference; clinical utility thresholds for LV mass need prospective testing.
Future Directions: Prospective, multi-center validation and randomized implementation studies testing AI-LV mass–guided prevention strategies, integration with other AI-derived phenotypes, and cost-effectiveness analyses.
BACKGROUND AND AIMS: The significance of left ventricular mass and chamber volumes from non-contrast computed tomography (CT) for predicting major adverse cardiovascular events (MACE) has not been studied. Our objective was to evaluate the role of artificial intelligence-enabled multi-chamber cardiac volumetry from non-contrast CT for long-term risk stratification in asymptomatic subjects without known coronary artery disease. METHODS: Our study included 2022 asymptomatic individuals (55.6 ± 9.0 years; 59.2 % male) from the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) trial. Multi-chamber cardiac volumetry was performed using deep-learning algorithms from routine non-contrast CT scans for coronary artery calcium scoring. MACE was defined as cardiac death, acute coronary syndrome, and late (>180 days) revascularization. RESULTS: A total of 215 individuals (11 %) suffered MACE at a mean follow-up of 13.9 ± 3 years. Individuals with MACE had higher left ventricular mass (115.1g vs. 105.2g, p < 0.001). In a multivariable analysis adjusted for cardiovascular risk factors and medications, left ventricular mass (HR 2.76, p<0.001) and coronary artery calcium score (HR 1.34, p<0.001) were independent predictors of long-term MACE. Adding left ventricular mass to the coronary calcium score improved the Receiver Operating Characteristic Area Under the Curve (AUC 0.753 vs 0.767, p=0.031) with continuous net reclassification index of 18 % (p=0.011). Left ventricular mass (HR 3.89, p<0.001), but not the coronary artery calcium score predicted cardiovascular death. CONCLUSIONS: Left ventricular mass quantified automatically by AI from routine non-contrast CT independently predicted long-term MACE over and above the coronary calcium score in asymptomatic participants without known coronary artery disease.
2. Genetic Predisposition to Low-Density Lipoprotein Cholesterol and Incident Type 2 Diabetes.
Across 361,082 UK Biobank participants with 13.7 years median follow-up, higher LDL-C genetic predisposition was associated with lower T2D risk, whereas lower LDL-C genetic predisposition increased T2D risk; CAD risk increased with LDL-C PRS. Findings clarify lipid–diabetes trade-offs across distinct genetic mechanisms.
Impact: The study disentangles genetic mechanisms linking LDL-C and T2D, informing interpretation of LDL-lowering therapy’s diabetogenic signal and advancing precision risk communication.
Clinical Implications: While not directly about drugs, results support vigilant glycemic monitoring when aggressively lowering LDL-C and frame patient counseling that CAD benefits outweigh modest T2D risk, which may be mechanism-dependent.
Key Findings
- Very high LDL-C PRS was associated with lower incident T2D risk (HR 0.72; 95% CI 0.66-0.79), while very low LDL-C PRS increased T2D risk (HR 1.26; 95% CI 1.15-1.38).
- Familial hypercholesterolemia status was associated with the lowest T2D risk (HR 0.65), whereas APOB/PCSK9 pLOF variants conferred higher T2D risk (HR 1.48).
- CAD risk increased directly with LDL-C PRS, confirming the gradient of atherogenic risk by genetic LDL-C burden.
Methodological Strengths
- Very large, prospective, population-based cohort with whole-exome and genome-wide genotyping.
- Rigorous multivariable adjustment including genetic principal components and medication use.
Limitations
- UK Biobank participation and ancestry composition may limit generalizability; residual confounding in observational genetics persists.
- Genetic associations do not equate to pharmacologic causality; translational relevance to specific LDL-lowering agents varies.
Future Directions: Mechanistic studies to dissect pathways linking low LDL-C genetic architectures to diabetogenesis, and pharmaco-genetic analyses to map agent-specific risk.
IMPORTANCE: Treatment to lower high levels of low-density lipoprotein cholesterol (LDL-C) reduces incident coronary artery disease (CAD) risk but modestly increases the risk for incident type 2 diabetes (T2D). The extent to which genetic factors across the cholesterol spectrum are associated with incident T2D is not well understood. OBJECTIVE: To investigate the association of genetic predisposition to increased LDL-C levels with incident T2D risk. DESIGN, SETTING, AND PARTICIPANTS: In this large prospective, population-based cohort study, UK Biobank participants who underwent whole-exome sequencing and genome-wide genotyping were included. Participants were separated into 7 groups with familial hypercholesterolemia (FH), predicted loss of function (pLOF) in APOB or PCSK9 variants, and LDL-C polygenic risk score (PRS) quintiles. Data were collected between 2006 and 2010, with a median follow-up of 13.7 (IQR, 12.9-14.5) years. Data were analyzed from March 1 to November 1, 2024. EXPOSURES: LDL-C level, LDL-C PRS, FH, or pLOF variant status. MAIN OUTCOMES AND MEASURES: Cox proportional hazards regression models adjusted for age, sex, genotyping array, lipid-lowering medication use, and the first 10 genetic principal components were fitted to assess the association between LDL-C genetic factors and incident T2D and CAD risks. RESULTS: Among the 361 082 participants, mean (SD) age was 56.8 (8.0) years, 194 751 (53.9%) were female, and mean (SD) baseline LDL-C level was 138.0 (33.6) mg/dL. During the follow-up period, 22 619 (6.3%) participants developed incident T2D and 17 966 (5.0%) developed incident CAD. The hazard ratio for incident T2D was lowest in the FH group (0.65; 95% CI, 0.54-0.77), while the highest risk was in the pLOF group (1.48; 95% CI, 1.18-1.86). The association between LDL-C PRS and incident T2D was 0.72 (95% CI, 0.66-0.79) for very high LDL-C PRS, 0.87 (95% CI, 0.84-0.90) for high LDL-C PRS, 1.13 (95% CI, 1.09-1.17) for low LDL-C PRS, and 1.26 (95% CI, 1.15-1.38) for very low LDL-C PRS. CAD risk increased directly with the LDL-C PRS. CONCLUSIONS AND RELEVANCE: In this cohort study, LDL-C and T2D risks were inversely associated across genetic mechanisms for LDL-C variation. Further elucidation of the mechanisms associating low LDL-C risk with increased risk of T2D is warranted.
3. Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.
Across 23 studies (8,972 participants), antitrypanosomal therapy in chronic Chagas disease significantly reduced ECG progression, disease progression, cardiovascular death, and all-cause mortality versus control, supporting broader therapeutic use.
Impact: Provides outcome-level evidence that antiparasitic therapy improves cardiovascular and survival endpoints in a major neglected cardiomyopathy, informing global health policy and clinical management.
Clinical Implications: Clinicians should consider trypanocidal therapy in chronic Chagas disease to mitigate electrical and structural progression and reduce cardiovascular and overall mortality, while balancing drug tolerability.
Key Findings
- Antiparasitic therapy reduced ECG changes (RR 0.48; 95% CI 0.36–0.66) across 17 studies (n=4,994).
- Reductions were also observed in disease progression, cardiovascular death, and overall mortality versus control.
- Comprehensive search and PROSPERO registration; results robust despite heterogeneity and mixed study designs.
Methodological Strengths
- Systematic review/meta-analysis with comprehensive database coverage and PROSPERO registration.
- Focus on clinically meaningful outcomes beyond parasitological measures.
Limitations
- Considerable heterogeneity and inclusion of observational studies; risk of bias ranges from low to intermediate.
- Variation in dosing, timing, and follow-up across studies limits precision of effect estimates.
Future Directions: Well-powered randomized trials with standardized regimens and long-term follow-up to refine effect sizes and identify subgroups with maximal benefit; implementation studies in endemic regions.
BACKGROUND: Endemic in more than 20 countries, Chagas disease affects 6.3 million people worldwide, leading to 28,000 new infections and 7700 deaths each year. Previous meta-analyses on antiparasitic treatment need updates to encompass recent studies and to assess key clinically meaningful endpoints. This study aims to evaluate the impact of antitrypanosomal therapy in preventing or reducing disease progression and mortality in chronic Chagas disease. METHODS: We performed a systematic review and meta-analysis of studies reporting the cardiovascular outcomes of antitrypanosomal therapy in patients with chronic Chagas disease. We searched Ovid Embase, Ovid MEDLINE, Ovid Global Health, Scopus, Web of Science Core Collection, Cochrane Library, PubMed, Google Scholar, and Virtual Health Library databases from inception to May 18, 2024. We included aggregated data from randomized controlled studies and observational reports (full articles and abstracts) featuring antiparasitic interventions with benznidazole or nifurtimox compared to a control group. Primary outcomes were electrocardiogram (ECG) changes, disease progression, cardiovascular death, and overall mortality. A customized risk of bias scale assessed the methodological quality of studies, and a random-effects model estimated the pooled risk ratios. This investigation was registered in PROSPERO (CRD42023495755). FINDINGS: Out of 4666 reports screened, 23 met the pre-specified inclusion criteria (8972 participants). Compared to no treatment or placebo, antiparasitic treatment led to a reduction in i) ECG changes (17 studies, 4994 participants: risk ratio (RR): 0.48, 95% CI 0.36-0.66, p < 0.001; INTERPRETATION: We found compelling evidence that antiparasitic treatment significantly reduces the risk of ECG changes, disease progression, cardiovascular death, and overall mortality in chronic Chagas disease. Although the quality of evidence ranges from low to intermediate, with considerable heterogeneity across studies, the potential benefits are substantial. These findings support the broader use of trypanocidal therapy in the management of Chagas disease, though further research remains necessary. FUNDING: This study had no funding source.